CCL20 and systemic sclerosis: Importantly, CCL20 was significantly up-regulated in dermal fibroblasts of dcSSc patients (disease duration of < 2 years) compared with those cells of healthy controls (3 [0.75–3] versus 0 [0–1.5], p = 0.046), which is consistent with a previous finding that CCL20 expression is increased in dermal fibroblasts of early SSc patients [13].